Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2023-06-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞自愿披露关于控股子公司新冠疫苗SCTV01E-2获得国内药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding its controlling subsidiary receiving approval from the National Medical Products Administration for a clinical trial of a new COVID-19 vaccine candidate. The text includes details about the clinical trial approval, product description, regulatory context, and risk warnings. It is an announcement of a regulatory approval event and related information, not a financial report, earnings release, or management discussion. The document length is short (2224 characters) and it does not contain financial statements or detailed financial data. It is not a report publication announcement since it does not mention an attached report or provide a link to a report. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about clinical trial approval and risk disclosure.
2023-06-29 Chinese
神州细胞2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2023 first extraordinary general meeting of shareholders of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the meeting date, attendance, voting results, and legal witness statements. It does not contain financial statements or detailed financial analysis but focuses on the voting outcomes and procedural compliance of the shareholder meeting. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and it is not an announcement of a report publication but the actual voting results. Therefore, the correct classification is DVA with high confidence.
2023-06-12 Chinese
神州细胞自愿披露关于子公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. about its subsidiary obtaining a drug registration certificate from the National Medical Products Administration. It details the drug's basic information, approval, and potential impact on the company. The document is short (1392 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about a significant corporate event related to product approval.
2023-06-12 Chinese
北京市金杜律师事务所关于北京神州细胞生物技术集团股份公司2023年第一次临时股东大会的法律意见书
Regulatory Filings
2023-06-12 Chinese
神州细胞2023年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2023 First Extraordinary General Meeting (EGM) Meeting Materials" of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It contains detailed information about the meeting agenda, voting procedures, and a specific proposal regarding a related-party lease transaction. The content is focused on the materials provided for the shareholders to review before the EGM, including legal notices, meeting rules, agenda items, and the proposal for shareholder approval. There are no financial statements or earnings data, nor is this a transcript or announcement of results. The document is clearly the meeting materials distributed for the EGM, which fits the definition of AGM Information (AGM-R), as it is the presentation and materials shared during a shareholders meeting (in this case, an extraordinary general meeting). The document length (4902 characters) and detailed content support this classification rather than a simple announcement or voting results report.
2023-05-31 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司之控股子公司签订租赁合同暨关联交易事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding a related-party transaction involving a lease contract between a controlling subsidiary of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. and an affiliated party. It includes comprehensive information about the transaction, the parties involved, pricing, terms, necessity, impact on the company, and the internal approval process including board and independent directors' opinions. The document also contains the sponsor's verification opinion. The content is focused on the audit and verification of the related-party transaction rather than a full annual report, earnings release, or other financial report. It is not a brief announcement or a simple notice but a standalone audit-type report on the related-party transaction. Therefore, it fits best under Audit Report / Information (AR). The document length (5443 characters) supports it being a full report rather than a short announcement or certification. FY 2023
2023-05-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.